Skip to main content
An official website of the United States government

Chemopreventive Agent Development

Designs, develops, implements, and monitors research on interventions that may block, reverse, or delay the early stages of cancer. Investigates nutrients, micronutrients, natural products, pharmacologic agents, biomolecules, and vaccines from preclinical to early-phase I clinical studies. Helps investigators to bridge the gaps between biology and identifying potential targets, and between discovery of targets and agents and clinical testing in people.

On This Page

  • All Heading 2s will automatically be pulled in to this list.
  • Do not edit the content on this template.

Major Programs

Staff List

Photo Name, Email, Phone Room Group(s)/Office
Asefa, Wosene
 wosene.asefa@nih.gov
240-276-6422 		5E504 Program Support Assistant | Chemopreventive Agent Development
Biswas, Kajal, Ph.D.
 kajal.biswas2@nih.gov
240-276-5614 		5E540 Program Officer | Chemopreventive Agent Development
Cholewa, Brian, Ph.D.
 brian.cholewa@nih.gov
240-276-7545 		5E446 Deputy Chief | Chemopreventive Agent Development
Clifford, John, Ph.D.
 john.clifford@nih.gov
202-235-4482 		5E430 Program Officer | Chemopreventive Agent Development
Gunasekharan, Vignesh, Ph.D.
 vignesh.gunasekharan@nih.gov
240-276-5814 		5E438 Program Officer | Chemopreventive Agent Development
Mohammed, Altaf, Ph.D.
 altaf.mohammed@nih.gov
240-276-6082 		5E542 Deputy Chief | Chemopreventive Agent Development
Nalli, Ancy, Ph.D., M.S.
 ancy.nalli@nih.gov
202-276-5265 		5E536 Program Officer | Chemopreventive Agent Development
Sei, Shizuko, M.D.
 shizuko.sei@nih.gov
240-276-5005 		5E452 Co-Chief | Chemopreventive Agent Development
Shoemaker, Robert, Ph.D.
 robert.shoemaker@nih.gov
240-276-7077 		5E454 Co-Chief | Chemopreventive Agent Development
Acting Chief | Nutritional Science
Vlad, Anda, M.D., Ph.D.
 anda.vlad@nih.gov
240-276-6422 		5E538 Program Officer | Chemopreventive Agent Development

Grants

PI Name PI Organization Title Grant Number Program Official
Nath, Kavindra

University Of Pennsylvania
United States

 Metabolic Biomarkers of Response of Mantle Cell Lymphoma to Bruton Tyrosine Kinase Inhibition 5R01CA228457-05 Nicholas Hodges, Ph.D.
Nelson, Randy J.

West Virginia University
United States

 Mechanism Underlying Sleep Disruption by Mammary Tumors 5R21CA276027-02 Marjorie Perloff, M.D.
Neslund-Dudas, Christine Marie

Henry Ford Health + Michigan State University Health Sciences
United States

 HFH-MSU CSRN ACCrual Enrollment and Screening Site 3UG1CA287007-02S1 Elyse LeeVan, M.D., M.P.H.
Nguyen, Sang Minh

Vanderbilt University Medical Center
United States

 Gut Microbiome Profiles in Association with Breast Cancer Recurrence and Mortality 1R03CA292953-01 Gabriela Riscuta, M.D., CNS
Nicolson, Fay

Dana-Farber Cancer Inst
United States

 SESORRS endoscopy for the staging and evaluation of colorectal cancer 5R00CA266921-04
NINA, BHARDWAJ,

ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
United States

 Immune determinants modulating cancer development in Lynch Syndrome 1UG3CA290517-01
Noble, Mark D

University Of Rochester
United States

 Prevention and treatment of paclitaxel-induced peripheral neuropathy 5R21CA277447-02 Rachel Altshuler, Ph.D.
Nolan, Michael Warren

North Carolina State University Raleigh
United States

 Evaluation of TRPM8-expressing neurons as novel regulators of acute radiotherapy-associated pain in patients with head and neck cancer 5R37CA248797-05 Asad Umar, D.V.M., Ph.D.
Nyamathi, Adeline M

University Of California-Irvine
United States

 Secondary Cervical Cancer Prevention of Vulnerable Women with HPV and HIV Co-infection in India 3R01CA285063-03S2 Vikrant Sahasrabuddhe, M.B.B.S., M.P.H., Dr.P.H.
Oberg, Ann Laura

Mayo Clinic Rochester
United States

 Management and Data Coordination Unit for PCDC 5U24CA274496-04 Guillermo Marquez, Ph.D.
Ochoa, Augusto C.

Lsu Health Sciences Center
United States

 Gulf South Clinical Trials Network (Gulf South NCORP) 3UG1CA189854-11S1 Brandy Heckman-Stoddard, Ph.D., M.P.H.
Olopade, Olufunmilayo F.

University Of Chicago
United States

 The Funding Mechanism of the Pilot Trial 5R01CA276652-03 Brandy Heckman-Stoddard, Ph.D., M.P.H.
Ondrey, Frank G.

University Of Minnesota
United States

 Pioglitazone-Metformin Combination Treatment for High Risk Oral Preneoplasia 5R01CA254270-04 Malgorzata Wojtowicz, M.D.
Onitilo, Adedayo A

Marshfield Clinic Research Foundation
United States

 Wisconsin NCI Community Oncology Research Program (WiNCORP) 3UG1CA189956-11S1 Vanessa A. White, M.P.H.
Osarogiagbon, Raymond U

Baptist Memorial Hospital - Tipton
United States

 Baptist Memorial Health Care/Mid South NCORP Consortium 3UG1CA189873-11S1 Brandy Heckman-Stoddard, Ph.D., M.P.H.